Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Surveillance of Suspected Dengue Cases for Access to Care for Subjects Identified as Seronegative or Undetermined at Baseline and Who Received CYD Dengue Vaccine in CYD15, CYD13, CYD29, CYD64, CYD65 Trials in Colombia

Trial Profile

Surveillance of Suspected Dengue Cases for Access to Care for Subjects Identified as Seronegative or Undetermined at Baseline and Who Received CYD Dengue Vaccine in CYD15, CYD13, CYD29, CYD64, CYD65 Trials in Colombia

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 05 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CYD TDV (Primary)
  • Indications Dengue
  • Focus Pharmacodynamics
  • Acronyms CYD00082
  • Sponsors Sanofi Pasteur

Most Recent Events

  • 03 Jan 2023 Planned End Date changed from 1 Oct 2027 to 11 Jan 2030.
  • 03 Jan 2023 Planned primary completion date changed from 1 Oct 2027 to 11 Jan 2030.
  • 08 Jun 2021 Planned End Date changed from 1 Nov 2027 to 1 Oct 2027.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top